GW Pharmaceuticals PLC- Stock Forecast, Price & News

GW Pharmaceuticals PLC-'s stock was trading at $86.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, GWPH stock has increased by 15.3% and is now trading at $100.18.
View which stocks have been most impacted by COVID-19.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GW Pharmaceuticals PLC- in the last year. There are currently 3 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) released its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($0.02) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.04) by $0.02. The biopharmaceutical company had revenue of $121.30 million for the quarter, compared to analyst estimates of $94.57 million. GW Pharmaceuticals PLC- had a negative net margin of 12.56% and a negative return on equity of 7.71%. The firm's revenue for the quarter was up 68.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.21 EPS.
View GW Pharmaceuticals PLC-'s earnings history.

13 equities research analysts have issued 1-year price targets for GW Pharmaceuticals PLC-'s stock. Their forecasts range from $128.00 to $275.00. On average, they anticipate GW Pharmaceuticals PLC-'s stock price to reach $185.08 in the next year. This suggests a possible upside of 84.8% from the stock's current price.
View analysts' price targets for GW Pharmaceuticals PLC-.

GW Pharmaceuticals PLC- saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 4,490,000 shares, an increase of 14.5% from the July 30th total of 3,920,000 shares. Based on an average daily trading volume, of 339,500 shares, the short-interest ratio is presently 13.2 days. Currently, 17.6% of the company's stock are short sold.
View GW Pharmaceuticals PLC-'s Short Interest.

Some companies that are related to GW Pharmaceuticals PLC- include Dr.Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), GRIFOLS S A/S (GRFS), Elanco Animal Health (ELAN), Teva Pharmaceutical Industries (TEVA), CureVac B.V. (CVAC), GALAPAGOS NV/S (GLPG), Mylan (MYL), Jazz Pharmaceuticals (JAZZ), Ascendis Pharma A/S (ASND), Myokardia (MYOK), Ionis Pharmaceuticals (IONS), Mirati Therapeutics (MRTX), ACADIA Pharmaceuticals (ACAD) and Perrigo (PRGO).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other GW Pharmaceuticals PLC- investors own include Canopy Growth (CGC), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Tesla (TSLA), Netflix (NFLX), Gilead Sciences (GILD), Cronos Group (CRON), Aurora Cannabis (ACB) and Intel (INTC).

GW Pharmaceuticals PLC- trades on the NASDAQ under the ticker symbol "GWPH."

GW Pharmaceuticals PLC-'s stock is owned by a number of retail and institutional investors. Top institutional investors include Laidlaw Wealth Management LLC (11.80%), Federated Hermes Inc. (2.65%), Victory Capital Management Inc. (1.85%), M&G Investment Management Ltd. (1.72%), Point72 Asset Management L.P. (1.66%) and Bank of New York Mellon Corp (1.20%). Company insiders that own GW Pharmaceuticals PLC- stock include Adam D George, Cabot Brown, Catherine J Mackey, Christopher J Tovey, Douglas B Snyder, Geoffrey W Dr Guy, James Noble, Julian S Gangolli, Justin D Gover, Scott M Giacobello, Volker Knappertz and William A Waldegrave.
View institutional ownership trends for GW Pharmaceuticals PLC-.

GWPH stock was sold by a variety of institutional investors in the last quarter, including River & Mercantile Asset Management LLP, M&G Investment Management Ltd., Bank of America Corp DE, Victory Capital Management Inc., FMR LLC, FMR LLC, Tekla Capital Management LLC, and Nuveen Asset Management LLC. Company insiders that have sold GW Pharmaceuticals PLC- company stock in the last year include Cabot Brown, Douglas B Snyder, Geoffrey W Dr Guy, Justin D Gover, Scott M Giacobello, and Volker Knappertz.
View insider buying and selling activity for GW Pharmaceuticals PLC-.

GWPH stock was acquired by a variety of institutional investors in the last quarter, including Laidlaw Wealth Management LLC, Point72 Asset Management L.P., Bank of New York Mellon Corp, Bellevue Group AG, Federated Hermes Inc., Bank of Montreal Can, Candriam Luxembourg S.C.A., and Marshall Wace LLP.
View insider buying and selling activity for GW Pharmaceuticals PLC-.

Shares of GWPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of GWPH stock can currently be purchased for approximately $100.18.

GW Pharmaceuticals PLC- has a market capitalization of $3.11 billion and generates $311.33 million in revenue each year. The biopharmaceutical company earns $-9,020,000.00 in net income (profit) each year or ($0.24) on an earnings per share basis. GW Pharmaceuticals PLC- employs 791 workers across the globe.

The official website for GW Pharmaceuticals PLC- is www.gwpharm.com.

GW Pharmaceuticals PLC-'s mailing address is SOVEREIGN HOUSE VISION PARK HISTON, CAMBRIDGE X0, CB24 9BZ. The biopharmaceutical company can be reached via phone at 44-12-2326-6800 or via email at [email protected]